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Research on improved treatment of HIV infection and
pre-exposure prophylaxis (PrEP) continues. Poor adher-
ence to treatment is the critical risk factor for virologic
failure and resistance development, and long-acting for-
mulations of anti-HIV medications that need only infre-
quent dosing may facilitate long-term therapeutic
responses. However, such formulations and long-term
persistence of drug are associated with challenges, such
as safety and selective pressure of the drug in case of
resistance.
Furthermore, to prevent transmission of HIV, long-
acting injectable formulations of ARV agents with infre-
quent dosing may be advantageous over daily oral drug
intake. However, the knowledge on protective drug con-
centrations and frequency of dosing is poor to date and
implementation globally is challenging.
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